Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.

Haematologica - 1 Aug 2015

Daver Naval, Cortes Jorge, Newberry Kate, Jabbour Elias, Zhou Lingsha, Wang Xuemei, Pierce Sherry, Kadia Tapan, Sasaki Koji, Borthakur Gautam, Ravandi Farhad, Pemmaraju Naveen, Kantarjian Hagop, Verstovsek Srdan

Abstract excerpt

Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally twice daily in continuous 28-day cycles, plus 5 mg lenalidomide orally once daily on days 1-21. Thirty-one patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrimidines

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 26088933
DOI: 10.3324/haematol.2015.126821
PMCID: PMC5004422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.PMID 26088933Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Efficacy of ruxolitinib for myelofibrosis.Semantic proximity Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.Semantic proximity Read ↗

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Semantic proximity Read ↗

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.Semantic proximity Read ↗

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Semantic proximity Read ↗

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity Read ↗

Rationale for combination therapy in myelofibrosis.Semantic proximity Read ↗

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.Semantic proximity Read ↗

Practical management of myelofibrosis with ruxolitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.